Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

Inclusion criteria

Subject must have a pathologically documented, definitively diagnosed, multiple myeloma relapsed, or refractory progressive disease after at least 2 lines of therapy for multiple myeloma. Prior therapeutic treatment or regimens must include a proteasome inhibitor and lenalidomide.
Subject must be willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines).
Measurable disease (assessed within 28 days prior to day 1)
Eastern Cooperative Oncology Group (ECOG) performance status of <= 2.
Other Inclusion Criteria May Apply

Exclusion Criteria

Currently receiving treatment in another investigational device or drug study, or less than 28 days or 5 half-lives whichever is shorter since ending treatment on another investigational device or drug study(s).
Previously received an allogeneic stem cell transplant and the occurrence of one or more of the following: received the transplant within 6 months prior to study day 1;received immunosuppressive therapy within the last 3 months prior to study day 1;having signs or symptoms of acute or chronic graft-versus-host disease.
Autologous stem cell transplant < 90 days prior to study day 1.
Multiple myeloma with IgM subtype.
POEMs syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
Plasma cell leukemia (> 2.0 X109/L circulating plasma cells by standard differential).
Waldenstrom's macroglobulinemia.
Other Exclusion Criteria May Apply